

**Bereskin & Parr**

Barristers and Solicitors/Patent and Trade Mark Agents  
Practice Restricted to Intellectual Property Law

Anita Nador B.A. (Molec. Biophys./Biochem), LL.  
416 957 1684 anador@bereskinparr.com

Your Reference: 09/645,594  
Our Reference: 11157-14

March 1, 2002

**BY FACSIMILE AND DIRECT DELIVERY  
TO USPTO WITH ENCLOSURES ON  
MARCH 4, 2002**

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER CFR.1.56 and CFR 1.97(c)**

Commissioner of Patents and Trademarks  
Washington D.C. 20231  
U.S.A.

Dear Sirs:

**Re: INFORMATION DISCLOSURE STATEMENT UNDER  
37 CFR.1.56 and CFR 1.97(c)  
United States Patent Application No. 09/645,594  
Filed: August 25, 2000  
Title: Use Of A Charged Dextran As A Mucoactive Agent And Methods  
And Pharmaceutical Compositions Relating Thereto  
Inventor: Malcom King  
Group Art Unit: 1619  
Examiner: Lauren Q. Wells**

---

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, applicant hereby submits an Information Disclosure Statement including (1) a listing of patents and other publications of which applicant is aware on form PTO-1449; (2) a copy of each listed item.

In accordance with 37 CFR 1.98(c), where two or more patents or publications are merely cumulative, a copy of just one of these patents or publications is enclosed. Alternatively, where one such patent or publication is already of record, no further cumulative patents or publications are enclosed.

Since all the enclosures are in English an explanation of relevance is neither required nor provided.

RECEIVED

MAR 06 2002

RECEIVED  
TECH CENTER 1600/2900  
02 MAR -4 PM 2:13

This Information Disclosure Statement is filed subsequent to the issuance of the first Office Action but prior to the issuance of either a Final Action or a Notice of Allowance. In accordance with 37 CFR 1.97 (c)(1), (c)(2) and (e)(1), The information contained in the information disclosure statement was first cited in the International PCT Report not more than three months prior to the filing of the enclosed information disclosure statement. Also, please deduct the prescribed fee under 37 CFR 1.17(p) of \$180.00 from out deposit account no. 02-2095. Please also deduct any deficiencies to this deposit account.

In view of the forgoing, it is respectfully submitted that the Information Disclosure Statement should be considered by the Examiner during examination of this application.

Respectfully submitted,

**MALCOLM KING**



Anita Nador  
Registration No. 47,366

Bereskin & Parr  
(Agents of the Applicant)  
Box 401, 40 King Street West  
Toronto, Ontario, Canada  
M5H 3Y2

(416) 364-7311